US Patent
US8524733 — Benzoquinoline inhibitors of vesicular monoamine transporter 2
Composition of Matter · Assigned to Auspex Pharmaceuticals Inc · Expires 2031-04-03 · 5y remaining
Vulnerability score
18/100
Ironclad — strong claim type, well-established, deep family
What this patent protects
This patent protects new benzoquinoline inhibitors of the vesicular monoamine transporter 2 (VMAT2) and their pharmaceutical compositions.
USPTO Abstract
The present invention relates to new benzoquinoline inhibitors of vesicular monoamine transporter 2 (VMAT2), pharmaceutical compositions thereof, and methods of use thereof.
Drugs covered by this patent
- Austedo (DEUTETRABENAZINE) · Teva
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.